Primary duodenogastric reflux in children and adolescents.
Primary duodenogastric reflux is a rare disorder in adults which has not yet been documented in children. Six young patients, aged 4.5 to 16.5 years (median 13.5 years) presented with atypical reflux symptoms persisting from 1 to 84 months (median 8 months) and unresponsive to classical antacid therapy. In all six patients, 24 h gastric bilimetry showed excessive bile exposures for absorbances ranging from 0.25 to 0.60. The fraction of time (supine period) above the 0.25 absorbance threshold ranged from 30% to 75% while the 95th percentile value for healthy adults is 31%. In all patients tested, hepato-iminodiacetic acid scintigraphy revealed the occurrence of a massive duodenogastric reflux and four out of five patients had an alkaline shift (fraction of time pH >8 on 24 h lower oesophageal pH monitoring) ranging from 4.2% to 20% (control values 0.0% to 2.9%). Endoscopic findings included abundant bilious gastric leak (6/6) and chronic prepyloric Helicobacter pylorinegative gastritis (2/6). Daily administration of cisapride, sucralfate with or without omeprazole resulted in an improvement of symptoms in five patients within 15 days. This treatment was ineffective in one patient who became symptom-free only after a surgical duodenal switch with fundoplication was performed.


CONCLUSIONS
primary duodenogastric reflux is a rare foregut disorder of unknown origin occurring in late childhood. If suspected, 24 h intragastric bilimetry appears to be a useful investigation to confirm the diagnosis.
Hermans
Dominique
D
Paediatric Gastroenterology Unit, Cliniques Universitaires St-Luc, 10 avenue Hippocrate, 1200 Brussels, Belgium.
Sokal
Etienne-Marc
EM
Collard
Jean-Marie
JM
Romagnoli
Renato
R
Buts
Jean-Paul
JP
D000293:Adolescent; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001530:Belgium; D001655:Bile Reflux / Q000175:diagnosis / Q000209:etiology; D002614:Chelating Agents; D002648:Child; D002669:Child Welfare; D002675:Child, Preschool; D020117:Cisapride / Q000627:therapeutic use; D004383:Duodenogastric Reflux / Q000175:diagnosis / Q000209:etiology*; D004386:Duodenum / Q000000981:diagnostic imaging / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D005745:Gastric Acidity Determination; D005753:Gastric Mucosa / Q000378:metabolism; D006801:Humans; D007098:Imino Acids; D008297:Male; D011877:Radionuclide Imaging; D012720:Severity of Illness Index; D013270:Stomach / Q000000981:diagnostic imaging; D013392:Sucralfate / Q000627:therapeutic use; D016896:Treatment Outcome
D000897:Anti-Ulcer Agents; D002614:Chelating Agents; D007098:Imino Acids; D013392:Sucralfate; D020117:Cisapride; C008109:iminodiacetic acid